Bicistronic eukaryotic RNA virus expressing heterologous polypeptide; polio virus vector with encephalomyocarditis virus ribosome landing pad for use in recombinant vaccine or recombinant protein production in eukaryote cell

Download Bicistronic eukaryotic RNA virus expressing heterologous polypeptide; polio virus vector with encephalomyocarditis virus ribosome landing pad for use in recombinant vaccine or recombinant protein production in eukaryote cell

Post on 23-Nov-2016

212 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

<ul><li><p>Peptlde comprising human T-lymphocyte epttope of clrcum- sporozolte protein of Plasmodmm wvax; recombinant protein useful in malaria diagnosis and as a recombinant vaccine, monoclonal antibody Coun~ Queensland Inst Med Res World 9311 157, 10 June 1993 </p><p>A human T-lymphocyte epltope (I) of the cIrcumsporozolte (CS) protein of Plasnlodmm vii:IV or a fragment, derivative, homologue or analogue of (I) is claimed [I) is preferably recombinant or syntheUc and contains amino acids 1-373, 90-370, 230 368, 232-251,289-339, 339-358 or 349-368 of the CS protein The following are also clmmed (1) a native or recombinant vaccine containing (I), (2) the vaccine of (1) containing at least two peptldes or a single polypeptlde of at least two peptldes, where each peptlde has a different T-lymphocyte epltope, (2) a method for vaccinating a human against P wvar infection (e g malarm) involving administering (I), (3) an antibody specific for (I), preferably a polyclonal or monoclonal antzbody or a synthenc antibody, (4) use of (I) for vaccine production, (5) a method for detecting lymphocytes capable of prohferatlve response to P vwax involving a lymphocyte prohferatlon assay (LPA), (6) use of the LPA for human screening for infection with P vwar, and (7) a kit for detecting lymphocytes capable of proliferative response to P vwa~ containing (I) and reagents for a LPA 101-93 </p><p>Patent Report </p><p>Bicistronic eukaryotic RNA virus expressing heterologous polypeptide; polio virus vector with encephalomyocardltlS virus ribosome landing pad for use in recombinant vaccine or recombinant protein production In eukaryote cell Brlt Technol UK 2262 099, 9 June 1993 </p><p>A new bxclstronIc eukaryotlc RNA virus is able to replicate and express a foreign polypeptlde m infected cells The virus has a genome with (in 5' to 3' order) a first ribosome landing pad (RLP) operably linked to a first (native) gene, a translational stop codon, and a second RLP, independent of the first RLP and operably hnked to a second (foreign) gene Preferably, the virus is a plcornavirus (e g polio virus), and the foreign RLP is from another plcornavlrus, e g encephalo- myocardltlS virus The first RLP IS present within a first part of the Y-non-coding region (NCR) of poho virus essential for viral growth and the second RLP are present m the second part of the 5'-NCR The foreign polypeptlde may be an antigen from HIV virus, hepatitis virus, human rhlnovlrus, herpes simplex virus, foot-and-mouth-disease virus, influenza virus, coxsackIe wrus, CD4, Chlamvdla trachomatts or Plasmodtum falctpat um, or may be calcltonln, tissue plasmlnogen-activator, human somatotropln, or granulocyte-macrophage or granulo- cyte colony stimulating factor The viruses are useful as vectors for recombinant vaccine or protein productmn 103-93 </p><p>Pneumocystts carton recombinant major surface antigen production; for use in recombinant vaccine production and in diagnosis of P. carmu infection in AIDS patient U S Dept Health Human Serv USA 7958 683, 1 April 1993 </p><p>A major surface glycoproteln antigen (I) of Pneumoo,stls cartnu is disclosed It is encoded by a multlcopy gene family (PC3, PC5, PC14, GP3, GP22, GP46) and has a tool wt of 123000 It is relatively rich in Cys residues (5 5%), which are very strongly conserved, and contains a well conserved hydrophoblc region at the C-terminus Also disclosed are (1) DNA encoding (I) or allellc variants, (2) a method for obtaining the (I)-encodlng DNA by screening a eDNA gene bank of P carmu with an antibody specific for (I) to identify clones encoding gp116, and using these clones to reveal the presence of multiple genes encoding (I), (3) a recombinant vaccine containing (I) or a derivative, and (4) DNA encoding a mammahan P carlnu (I) which IS a composite (or consensus sequences) or multiple genes encoding (I) (I)can be used in vaccines against P carmu infection in HIV virus-infected (AIDS) patients and m studies aimed at developing potential preventmn or therapy strategies The DNA can be used for polymerase chain reaction DNA primer construction for refection diagnosis Immunoprophylaxls does not cause adverse effects 102-93 </p><p>Recombinant DNA encoding Pseudomonas exotoxln and influenza A virus or HIV virus-1 surface antigen fusion protein, recombinant protein cell display and use as a vaccine against parasite and virus infection and tumour growth Merk USA Eur 541 335, 12 May 1993 </p><p>A recombinant DNA fragment encoding a fusion protein of a modified Pseudomonas exotoxln and a protein (I) that is exogenous to an antigen-presenting cell is new The fusion protein is preferably at least pamally expressed on the surface of, or lnternahzed by, an antigen-presenting cell (I) IS preferably of virus origin Partial or whole expression of the fusion protein on an antigen-presenting cell elicits an immune response by cytotoxlc T-lymphocytes The following are also new (1) a transformant containing the DNA fragment encoding the fusion protein, (2) the recombinant DNA fragment where the modified Pseudomonas exotoxm lacks a functional ADP rlbosylatlng domain, (3) recombinant DNA encoding a fusion protein with residues 57-68 of influenza A virus matrix protein as the viral protein, (4) recombinant DNA encoding a fusion protein with the gag protein of HIV virus-l, and (5) recombinant DNA encoding a fusion protein of influenza A wrus nucleoprotein as the wral protein The recombinant proteins are useful for recombinant vaccine construction 104-93 </p><p>Vaccine, Vol 11, Issue 13, 1993 1357 </p></li></ul>